Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

Cancer

Volumn 119, Issue 20, 2013, Pages 3653-3661

  Barnett, Jason C ^a   Alvarez Secord, Angeles ^b   Cohn, David E ^c   Leath II, Charles A ^d   Myers, Evan R ^e   Havrilesky, Laura J ^b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bevacizumab; cost effectiveness; ICON7 trial; International Collaboration on Ovarian Neoplasms; ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

BEVACIZUMAB; COST EFFECTIVENESS; ICON7 TRIAL; INTERNATIONAL COLLABORATION ON OVARIAN NEOPLASMS; OVARIAN CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MARKOV CHAINS; MODELS, THEORETICAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84885172921     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28283     Document Type: Article

References (30)

1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365: 2473-2483.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365: 2484-2496.
3. Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr,. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011; 29: 1247-1251.
4. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30: 2039-2045.
5. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract LBA5002.
6. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25: 5180-5186. (Pubitemid 350232248)
7. Del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T,. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012; 126: 369-374.
8. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26: 76-82.
9. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010; 28: 154-159.
10. Caplan AL,. Will evidence ever be sufficient to resolve the challenge of cost containment? J Clin Oncol. 2011; 29: 1946-1948.
11. Amir E, Seruga B, Martinez-Lopez J, et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol. 2011; 29: 2543-2549.
12. Fountzilas G, Kourea HP, Bobos M, et al. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res. 2011; 31: 3007-3018.
13. Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a Gynecologic Oncology Group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010; 119: 484-490.
14. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012; 13: 724-733.
15. Matsusaka S, Mishima Y, Suenaga M, et al. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer. 2011; 117: 4026-4032.
16. Mehta R, Kyshtoobayeva A, Kurosaki T, et al. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res. 2001; 7: 81-88. (Pubitemid 32110208)
17. Moroni M,. Predictive value of loci in VEGF pathway genes in bevacizumab treatment. Lancet Oncol. 2012; 13: 659-660.
18. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012; 30: 2119-2127.
19. Hoyle MW, Henley W,. Improved curve fits to summary survival data: application to economic evaluation of health technologies [serial online]. BMC Med Res Methodol. 2011; 11: 139.
20. Balu S, Thomas J 3rd,. Incremental expenditure of treating hypertension in the United States. Am J Hypertens. 2006; 19: 810-816. (Pubitemid 44107695)
21. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D,. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999; 15: 141-155. (Pubitemid 29093257)
22. Horsman J, Furlong W, Feeny D, Torrance G,. The Health Utilities Index (HUI): concepts, measurement properties and applications [serial online]. Health Qual Life Outcomes. 2003; 1: 54.
23. Lee CP, Chertow GM, Zenios SA,. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009; 12: 80-87.
24. Bansal V, Tewhey R, Leproust EM, Schork NJ,. Efficient and cost effective population resequencing by pooling and in-solution hybridization [serial online]. PLoS One. 2011; 6: e18353.
25. de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA,. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer. 2012; 118: 1032-1039.
26. Liberato NL, Marchetti M, Barosi G,. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25: 625-633. (Pubitemid 350002916)
27. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK,. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ("Arimidex," Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007; 106: 229-238. (Pubitemid 350045007)
28. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO. 17 trial. J Natl Cancer Inst. 2009; 101: 1182-1192.
29. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013; 14: 236-243.
30. Randall LM, Monk BJ,. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010; 117: 497-504.